Kim Bo-Young, Park Mi-Hyun, Woo Hae-Mi, Jo Hye-Yeong, Kim Ji Hoon, Choi Hyung Jin, Koo Soo Kyung
Division of Intractable Diseases, Center for Biomedical Sciences, Korea National Institute of Health, 187 Osongsaengmyeing2-ro, Cheongju-si, Chungcheongbuk-do, 28159, South Korea.
Department of Surgery, Eulji University Hospital, Daejeon, South Korea.
BMC Med Genet. 2017 Oct 2;18(1):106. doi: 10.1186/s12881-017-0465-9.
Multiple endocrine neoplasia type 1 (MEN1) syndrome is an autosomal dominant hereditary disorder characterized by the presence of endocrine tumors affecting the parathyroid, pancreas, and pituitary. A heterozygous germline inactivating mutation in the MEN1 gene (first hit) may be followed by somatic loss of the remaining normal copy or somatic mutations in the MEN1 gene (second hit). Whole-exome sequencing has been successfully used to elucidate the mutations associated with the different types of tumors.
We performed whole-exome sequencing (WES) on three parathyroid tumors, one pancreatic insulinoma, and a blood sample taken from the same patient with MEN1 to study tumor heterogeneity in MEN1 originating from different tumors. We identified a novel frame-shift deletion (c.1382_1383delAG, p.E461GfsX69) in the MEN1 gene using WES, which was confirmed by Sanger sequencing. WES and the SNP array revealed somatic LOH on chromosome 11 in parathyroid tumors (left upper, left lower, and right upper parathyroid). However, we did not detect a somatic MEN1 gene mutation or LOH in the pancreatic insulinoma. WES revealed two somatic functional variants outside the MEN1 gene in the pancreatic insulinoma.
This study revealed heterogeneity among tumors in the same patient with MEN1, suggesting that different tumor-specific tumorigenic mechanisms may contribute to the pathogenesis of MEN1 tumors. The present study supports the clinical applicability of the WES strategy to research on multiple tumor samples and blood.
1型多发性内分泌腺瘤病(MEN1)综合征是一种常染色体显性遗传性疾病,其特征是存在影响甲状旁腺、胰腺和垂体的内分泌肿瘤。MEN1基因中的杂合种系失活突变(首次打击)之后可能会出现剩余正常拷贝的体细胞丢失或MEN1基因中的体细胞突变(二次打击)。全外显子组测序已成功用于阐明与不同类型肿瘤相关的突变。
我们对来自一名患有MEN1的患者的三个甲状旁腺肿瘤、一个胰腺胰岛素瘤以及一份血液样本进行了全外显子组测序(WES),以研究源自不同肿瘤的MEN1中的肿瘤异质性。我们使用WES在MEN1基因中鉴定出一个新的移码缺失(c.1382_1383delAG,p.E461GfsX69),该缺失经桑格测序得以证实。WES和单核苷酸多态性阵列显示甲状旁腺肿瘤(左上、左下和右上甲状旁腺)中11号染色体存在体细胞杂合性缺失。然而,我们在胰腺胰岛素瘤中未检测到体细胞MEN1基因突变或杂合性缺失。WES显示胰腺胰岛素瘤中MEN1基因外存在两个体细胞功能变体。
本研究揭示了同一名MEN1患者肿瘤之间的异质性,表明不同的肿瘤特异性致瘤机制可能参与了MEN1肿瘤的发病过程。本研究支持WES策略在多个肿瘤样本和血液研究中的临床适用性。